Vestal Point Capital LP Invests $33.77 Million in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Vestal Point Capital LP bought a new stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 760,000 shares of the biopharmaceutical company’s stock, valued at approximately $33,767,000. Agios Pharmaceuticals makes up 2.6% of Vestal Point Capital LP’s portfolio, making the stock its 15th largest position. Vestal Point Capital LP owned approximately 1.33% of Agios Pharmaceuticals as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Marshall Wace LLP boosted its position in shares of Agios Pharmaceuticals by 307.8% during the 2nd quarter. Marshall Wace LLP now owns 1,133,735 shares of the biopharmaceutical company’s stock valued at $48,887,000 after purchasing an additional 855,739 shares in the last quarter. Frazier Life Sciences Management L.P. grew its holdings in shares of Agios Pharmaceuticals by 66.7% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 871,974 shares of the biopharmaceutical company’s stock valued at $37,600,000 after acquiring an additional 348,808 shares in the last quarter. Candriam S.C.A. acquired a new position in shares of Agios Pharmaceuticals in the second quarter worth $13,922,000. D. E. Shaw & Co. Inc. raised its holdings in shares of Agios Pharmaceuticals by 87.3% during the second quarter. D. E. Shaw & Co. Inc. now owns 678,234 shares of the biopharmaceutical company’s stock worth $29,245,000 after acquiring an additional 316,100 shares in the last quarter. Finally, Panagora Asset Management Inc. acquired a new stake in Agios Pharmaceuticals during the second quarter valued at $7,540,000.

Insider Buying and Selling

In related news, CFO Cecilia Jones sold 2,542 shares of the business’s stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $49.03, for a total transaction of $124,634.26. Following the transaction, the chief financial officer now directly owns 20,158 shares in the company, valued at $988,346.74. The trade was a 11.20 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 4.93% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

AGIO has been the subject of several research reports. Leerink Partnrs lowered Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, September 27th. Leerink Partners downgraded shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $60.00 to $56.00 in a research report on Friday, September 27th. Raymond James restated an “outperform” rating and set a $51.00 price target on shares of Agios Pharmaceuticals in a research note on Thursday, October 10th. Royal Bank of Canada restated an “outperform” rating and issued a $55.00 target price on shares of Agios Pharmaceuticals in a report on Friday, November 1st. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a report on Friday, September 20th. Five equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $52.33.

Agios Pharmaceuticals Stock Down 0.7 %

Shares of NASDAQ AGIO opened at $58.66 on Friday. Agios Pharmaceuticals, Inc. has a 12 month low of $20.96 and a 12 month high of $62.58. The company has a market cap of $3.35 billion, a P/E ratio of 5.16 and a beta of 0.75. The business’s 50 day moving average is $48.19 and its two-hundred day moving average is $45.13.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.